Clinical Trial

Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).

Study acronym: PBMC
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-16; most recent amendment 2026-04-16.
Trial Details
NCT Number NCT05161702
Lead Sponsor SCF Pharma
Conditions Resolution of Inflammation, Reduction of Cell Proliferation
Enrollment 200 participants
Start Date 2019-03-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-17